David Andrew Sinclair Quotes

I had seen a Pfizer's pilot plant in 1965 and decided that, 'I'll build a Pfizer.' If not Pfizer, I have built Dr Reddy's, which is no less respectable.

There's always going to be the need for new medications, better medications.

In general, drug companies are reasonably good at developing new treatments, and there's also a lot of good in the industry.

I keep encouraging the pharmaceutical companies to put more money into R&D.

I really was inspired by the possibility of more directly being involved in the development of drugs myself.

To start with, pharma was an industry based on innovation, drug discovery.

I'd like to focus on my life on creating new medicines for people who are suffering from rare disease.

And there are lots of drug companies that are working on cure or medicine.

The United States has an active pharmaceutical industry that has brought huge benefits to the U.S. public. Most Americans, who benefit from these advances, have little understanding of how difficult it is to create an important new medical therapy and make it available to improve public health.

I fell in love with the science at Merck.

The problem we are trying to solve is that of drugs that would have never seen the light of day for reasons that have nothing to do with the inherent properties of drug candidates themselves and more to do with bureaucratic institutions within which they often sit.

Now, what tends to happen is that the stories get hyped. And the medicines are not quite as revolutionary and as dramatic as they seem to be. But, certainly, various phases of this problem are being attacked by the pharmaceutical companies.

Brand-name drugs have no competition, since the government grants them very long, exclusive marketing rights.

Pharmacology is benefited by the prepared mind. You need to know what you are looking for.

Drug discovery is terribly expensive, just to find out how one drug could or could not work and all its side effects.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.

I believe that life-saving, essential drugs should be freely available and the innovator should be paid a suitable royalty payment for his invention.

I want to make a drug. I want the science to be more than imaginary, where I think, 'We're learning these fundamental principles, blah, blah, blah, blah, blah.' I think we are doing that, but I want to do something really practical. I want to actually, in my lifetime, help people.

One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.

No pharmaceutical company is making money by selling biological knowledge - they make money by selling chemicals. So getting as much of that knowledge as possible into the efficiency of the Web-commerce world is going to make it faster to find those chemicals.

The pharmaceutical industry is spending $1 billion more each year on marketing and lobbying than it does on developing new and better drugs.

We have 28,000 drug patents held by American universities that are not being developed.

I am very passionate about India's place in bio-pharmaceuticals, and that is what I really want to drive and create leadership for in India because I really think it is possible.

I think Trump's going to make it easier to be a drug company in America.

I would say that the pharmaceutical industry is hyper-competitive from a global perspective.